Evidence map›Paper›PMID 41206814›Full record

ArticleInternational journal of hematology2026

Favorable response to daratumumab combination therapy in patients with multiple myeloma with an immature phenotype: a report from the J-CHARGE study group.

Noriyoshi Iriyama, Hitomi Nakayama, Masaru Nakagawa, Atsushi Takahata, Eriko Sato, Motoki Takano, Keigo Okada, Kohtaro Toyama, Toshiaki Hayashi, Takashi Abe and 16 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Noriyoshi IriyamaDepartment of Hematology and Rheumatology, National Hospital Organization Saitama Hospital, Saitama, Japan. iriyama.noriyoshi@nihon-u.ac.jp.ORCID http://orcid.org/0000-0001-9176-1988
Hitomi NakayamaDepartment of Hematology, Yokohama Municipal Citizen's Hospital, Kanagawa, Japan.
Masaru NakagawaDivision of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.
Atsushi TakahataDepartment of Hematology, Yokosuka Kyosai Hospital, Kanagawa, Japan.
Eriko SatoDepartment of Hematology, Juntendo University Nerima Hospital, Tokyo, Japan.
Motoki TakanoDepartment of Hematology, Fukushima Medical University, Fukushima, Japan.
Keigo OkadaDepartment of Hematology, Ome Medical Center, Tokyo, Japan.
Kohtaro ToyamaDepartment of Hematology, Fujioka General Hospital, Gunma, Japan.
Toshiaki HayashiDepartment of Hematology, Teine Keijinkai Hospital, Hokkaido, Japan.
Takashi AbeDepartment of Hematology, Niigata City General Hospital, Niigata, Japan.
Keisuke TanakaDepartment of Hematology, Institute of Science Tokyo, Tokyo, Japan.
Yasuhiko SenpukuDepartment of Hematology, Ageo Central General Hospital, Saitama, Japan.
Yuki OsadaDepartment of Hematology, Fraternity Memorial Hospital, Tokyo, Japan.
Junichi WatanabeDepartment of Hematology, TMG Asaka Medical Center, Saitama, Japan.
Koh YamamotoDepartment of Hematology, Yokohama City Minato Red Cross Hospital, Kanagawa, Japan.
Yasunobu SekiguchiDepartment of Hematology, Saitama Cancer Center, Saitama, Japan.
Gaku OshikawaDepartment of Hematology, Japanese Red Cross Musashino Hospital, Tokyo, Japan.
Yuta KimuraDepartment of Hematology, Japan Community Health Care Organization, Saitama Medical Center, Saitama, Japan.
Michihide TokuhiraDepartment of Hematology, Japan Community Health Care Organization, Saitama Medical Center, Saitama, Japan.
Ken SuzukiDepartment of Hematology, Fraternity Memorial Hospital, Tokyo, Japan.
Takashi KumagaiDepartment of Hematology, Ome Medical Center, Tokyo, Japan.
Takayuki IkezoeDepartment of Hematology, Fukushima Medical University, Fukushima, Japan.
Shigeo ToyotaDepartment of Hematology, Yokosuka Kyosai Hospital, Kanagawa, Japan.
Katsuhiro MiuraDivision of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.
Tomonori NakazatoDepartment of Hematology, Yokohama Municipal Citizen's Hospital, Kanagawa, Japan.
Takehiko MoriDepartment of Hematology, Institute of Science Tokyo, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aim and purposeThis study aimed to investigate the relationship between myeloma cell maturity, clinical profiles, and treatment outcomes in patients with multiple myeloma (MM). PATIENTS AND

methodsThe J-CHARGE-MM database includes data from 1200 MM patients diagnosed between January 2011 and January 2023. Immunophenotyping by flow cytometry using antibodies against CD38, CD49e, and MPC-1 was used to evaluate myeloma cell maturity.

resultsOut of 969 patients evaluable for myeloma cell maturity, 115 were classified as mature type, 626 as intermediate type, and 228 as immature type. Patients with the immature type were more likely to have the IgG type and 1q21 gain/amplification. Treatment response and outcome analysis showed that patients with the immature type had lower response rates and worse time to next treatment (TTNT) with bortezomib-based therapy compared to those with the mature or intermediate type. Lenalidomide-based therapy partially mitigated the adverse impact of the immature type. However, daratumumab combination therapy showed higher response rates and better TTNT, which was almost equivalent between the mature/intermediate and immature types.

conclusionStratifying patients with MM based on myeloma cell maturity provides meaningful information for choosing the best treatment strategy and improving patient outcomes.

Indexed as

Antibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsMultiple MyelomaAdultAgedAged, 80 and overBortezomibFemaleHumansImmunophenotypingLenalidomideMaleMiddle AgedPhenotypeTreatment OutcomeAntibodies, MonoclonalBortezomibdaratumumabLenalidomideBortezomibDaratumumabLenalidomideMultiple myelomaMyeloma cell maturity

Identifiers

PMID41206814

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.